Cargando…

Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)

OBJECTIVE: To compare, in real‐life settings, the retention rates of initial anti‐tumor‐necrosis factor (TNF) treatments (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) used as first‐line biotherapy for axial spondyloarthritis (axSpA), and evaluate treatment switches to another anti‐TNF in...

Descripción completa

Detalles Bibliográficos
Autores principales: Soubrier, Martin, Pereira, Bruno, Fan, Angelique, Frayssac, Thomas, Couderc, Marion, Malochet‐Guinamand, Sandrine, Mathieu, Sylvain, Tatar, Zuzana, Tournadre, Anne, Dubost, Jean‐Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585683/
https://www.ncbi.nlm.nih.gov/pubmed/30168265
http://dx.doi.org/10.1111/1756-185X.13375
_version_ 1783428749685948416
author Soubrier, Martin
Pereira, Bruno
Fan, Angelique
Frayssac, Thomas
Couderc, Marion
Malochet‐Guinamand, Sandrine
Mathieu, Sylvain
Tatar, Zuzana
Tournadre, Anne
Dubost, Jean‐Jacques
author_facet Soubrier, Martin
Pereira, Bruno
Fan, Angelique
Frayssac, Thomas
Couderc, Marion
Malochet‐Guinamand, Sandrine
Mathieu, Sylvain
Tatar, Zuzana
Tournadre, Anne
Dubost, Jean‐Jacques
author_sort Soubrier, Martin
collection PubMed
description OBJECTIVE: To compare, in real‐life settings, the retention rates of initial anti‐tumor‐necrosis factor (TNF) treatments (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) used as first‐line biotherapy for axial spondyloarthritis (axSpA), and evaluate treatment switches to another anti‐TNF inhibitor in the event of treatment failure. METHODS: We analyzed the medical records of all SpA patients (Assessment in Ankylosing Spondylitis International Working Group axial criteria) treated with ETN, IFX or ADA between 2001 and February 2015. Drug retention rates were calculated using the Kaplan‐Meier method and compared by means of the Cox extended model. Sub‐analyses were performed according to discontinuation reasons. RESULTS: Of the 249 SpA patients analyzed (135 radiographic cases, 114 non‐radiographic), 102 received ETN, 62 ADA, and 85 IFX. In total, 103 discontinued treatment. The retention rates of IFX, ADA and ETN were 67%, 59% and 56% after 3 years; 62%, 42% and 47% after 5 years; 55%, 42% and 24% after 8 years; 53%, 42% and 12% after 10 years, respectively. In multivariate analyses, the predictive factors for retention were: low BASDAI score (hazard ratio [HR]: 1.02 [1.01‐1.04]), high C‐reactive protein levels (HR: 0.98 [0.97‐0.99]), concomitant disease‐modifying therapy (HR: 0.4 [0.21‐0.75]), and radiographic SpA (HR: 1.5 [1.0‐2.52]). In total, 61 patients switched to another anti‐TNF therapy. No difference was observed among the three anti‐TNF therapies regarding median retention duration, although the retention rate proved higher for treatment switches from one monoclonal antibody to another. CONCLUSION: The retention rate in SpA patients proved high, with retention for IFX superior to that of ETN.
format Online
Article
Text
id pubmed-6585683
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65856832019-06-27 Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France) Soubrier, Martin Pereira, Bruno Fan, Angelique Frayssac, Thomas Couderc, Marion Malochet‐Guinamand, Sandrine Mathieu, Sylvain Tatar, Zuzana Tournadre, Anne Dubost, Jean‐Jacques Int J Rheum Dis Original Articles OBJECTIVE: To compare, in real‐life settings, the retention rates of initial anti‐tumor‐necrosis factor (TNF) treatments (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) used as first‐line biotherapy for axial spondyloarthritis (axSpA), and evaluate treatment switches to another anti‐TNF inhibitor in the event of treatment failure. METHODS: We analyzed the medical records of all SpA patients (Assessment in Ankylosing Spondylitis International Working Group axial criteria) treated with ETN, IFX or ADA between 2001 and February 2015. Drug retention rates were calculated using the Kaplan‐Meier method and compared by means of the Cox extended model. Sub‐analyses were performed according to discontinuation reasons. RESULTS: Of the 249 SpA patients analyzed (135 radiographic cases, 114 non‐radiographic), 102 received ETN, 62 ADA, and 85 IFX. In total, 103 discontinued treatment. The retention rates of IFX, ADA and ETN were 67%, 59% and 56% after 3 years; 62%, 42% and 47% after 5 years; 55%, 42% and 24% after 8 years; 53%, 42% and 12% after 10 years, respectively. In multivariate analyses, the predictive factors for retention were: low BASDAI score (hazard ratio [HR]: 1.02 [1.01‐1.04]), high C‐reactive protein levels (HR: 0.98 [0.97‐0.99]), concomitant disease‐modifying therapy (HR: 0.4 [0.21‐0.75]), and radiographic SpA (HR: 1.5 [1.0‐2.52]). In total, 61 patients switched to another anti‐TNF therapy. No difference was observed among the three anti‐TNF therapies regarding median retention duration, although the retention rate proved higher for treatment switches from one monoclonal antibody to another. CONCLUSION: The retention rate in SpA patients proved high, with retention for IFX superior to that of ETN. John Wiley and Sons Inc. 2018-08-30 2018-11 /pmc/articles/PMC6585683/ /pubmed/30168265 http://dx.doi.org/10.1111/1756-185X.13375 Text en © 2018 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Soubrier, Martin
Pereira, Bruno
Fan, Angelique
Frayssac, Thomas
Couderc, Marion
Malochet‐Guinamand, Sandrine
Mathieu, Sylvain
Tatar, Zuzana
Tournadre, Anne
Dubost, Jean‐Jacques
Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
title Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
title_full Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
title_fullStr Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
title_full_unstemmed Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
title_short Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
title_sort retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in auvergne (france)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585683/
https://www.ncbi.nlm.nih.gov/pubmed/30168265
http://dx.doi.org/10.1111/1756-185X.13375
work_keys_str_mv AT soubriermartin retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT pereirabruno retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT fanangelique retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT frayssacthomas retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT coudercmarion retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT malochetguinamandsandrine retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT mathieusylvain retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT tatarzuzana retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT tournadreanne retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance
AT dubostjeanjacques retentionratesofadalimumabetanerceptandinfliximabasfirstorsecondlinebiotherapiesforspondyloarthritispatientsindailypracticeinauvergnefrance